PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 17, 2026Journal of Cardiovascular Electrophysiology2 citations

Real‐World Adverse Events Associated With the Sphere‐9 Dual‐Energy Arrhythmia Ablation Catheter

View Full Paper
AMAhmed Ashraf MorganSASuraj AdhikariAAAdir Alper

Key Result

Analysis of 222 FDA MAUDE database reports for the Sphere-9 ablation catheter found 148 (67%) resulted in clinical events, including VT/VF, stroke/TIA, and sinus node dysfunction/AV block.

Key Points

  • To systematically assess adverse events reported for the Sphere‐9 dual-energy ablation catheter.
  • Queried the FDA MAUDE database from October 24, 2024 to October 24, 2025.
  • Included 222 reports related to the Sphere‐9 catheter in the final analysis.
  • Analyzed complications and causal relationships with the device.
  • 148 out of 222 reports (67%) resulted in clinical events.
  • 107 events were suspected to be related to the Sphere‐9 catheter, including 30 instances of VT/VF and 25 strokes.
  • 10 VT/VF cases were suspected to involve interactions between the catheter and ICD.

Study Design

Type

Observational (n=222)

Structured PICO

P
Population
222 adverse event reports related to the Sphere-9 catheter identified in the FDA MAUDE database
I
Intervention
Sphere-9 dual-energy arrhythmia ablation catheter (pulsed field and radiofrequency ablation)
O
Outcome
Adverse events related to the Sphere-9 cathetersafety

Real-world data from the FDA MAUDE database highlights that the Sphere-9 ablation catheter is associated with specific adverse events, notably arrhythmias such as VT/VF and AV block, as well as ICD-catheter interactions.

Abstract

ABSTRACT Introduction Sphere‐9 is a lattice tip ablation catheter (Medtronic, USA) capable of delivering both pulsed field and radiofrequency ablation. It is approved for the treatment of atrial fibrillation. Adverse events related to this device have been reported to national databases. A systematic assessment of these reports is needed to understand the nature of device‐related complications. Methods We queried the FDA Manufacturer and User Facility Device Experience (MAUDE) database between October 24, 2024 and October 24, 2025 to identify reports related to the Sphere‐9 catheter. A total of 222 reports were included in the final analysis. Results Of 222 reports, 148 (67%) resulted in clinical events. Of these, 107 were suspected to be related to the Sphere‐9, including: VT/VF during/following energy delivery ( n = 30), Stroke/TIA ( n = 25), sinus node dysfunction/AV block ( n = 23), pericardial effusion ( n = 7), coronary spasm ( n = 9), and phrenic nerve injury ( n = 2). Catheter/defibrillator (ICD) related interactions were suspected in 10 of the VT/VF reports. There were 65 catheter related reports that did not appear to be associated with adverse clinical events, which included tissue/char formation on the catheter tip ( n = 24), steam pop ( n = 25), and mechanical entrapment ( n = 7). Conclusion This early analysis of adverse events reported for the Sphere‐9 catheter highlights complications including arrhythmias, such as VT/VF and AV block, and the risks associated with ICD‐catheter related interactions.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Morgan et al. (2026) conducted an observational in Atrial fibrillation (n=222). Sphere-9 dual-energy arrhythmia ablation catheter was evaluated on Clinical events from device-related reports. Analysis of 222 FDA MAUDE database reports for the Sphere-9 ablation catheter found 148 (67%) resulted in clinical events, including VT/VF, stroke/TIA, and sinus node dysfunction/AV block.

synapsesocial.com/papers/6a095af37880e6d24efe0c38https://doi.org/10.1111/jce.70367
Ask AI
Helpful
Bookmark
Share
View Full Paper